Articles On Dimerix (ASX:DXB)
Title | Source | Codes | Date |
---|---|---|---|
ASX Market Close: IT sector leads market higher as Woodside falls on Scarborough cost hike | 23 July 2024
The ASX200 closed up half a percent at 7,971 points, as the market followed Wall Street’s strong lead. The IT sector lead the charge, up 1.62%, followed closely by Health Care 1.37% and Industrials 1.33%. The Energy sector lost 2% as the... |
themarketonline.com.au | DXB | 5 months ago |
ScoPo’s Powerplays: ASX health stocks rise amid renewed positive sentiment
ASX health stocks rise 2% in past five days as broader markets lift 0.6% Morgans upgrades disinfectant device maker Nanosonics after positive trading update Neuren receives rare paediatric disease designation from FDA for NNZ-2591 in Phel... |
Stockhead | DXB | 5 months ago |
Top 10 most traded ASX shares and US stocks in June
Mega ASX 200 iron ore shares BHP Group Ltd (ASX: BHP) and Fortescue Ltd (ASX: FMG) were the top two most traded ASX stocks last month among investors using the SelfWealth trading platform. Let's review the top 10. Top 10 most traded... |
Motley Fool | DXB | 5 months ago |
Investors’ sneak peek at biotech’s bright future
The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors Day one focus on new opportunities, finding the next blockbuster drug and re... |
Stockhead | DXB | 5 months ago |
Best 3 ASX 200 healthcare shares for price growth in FY24
In this article, we examine the best ASX 200 healthcare shares of FY24 based on share price growth. Here are the best performers, according to data from S & P Global Market Intelligence. The top 3 ASX 200 healthcare shares of FY2... |
Motley Fool | DXB | 6 months ago |
5 things to watch on the ASX 200 on Friday
On Thursday, the S&P/ASX 200 Index (ASX: XJO) had one of its best days of the year and stormed higher. The benchmark index rose 1.2% to 7,831.8 points. Will the market be able to build on this on Friday and end the week on a high? Her... |
Motley Fool | DXB | 6 months ago |
ASX Health Stocks: Which crypto high-flyer is investing in Singular Health?
Singular Health receives $1 million investment from prominent crypto figure Craig Sellars Adolescent recruitment into Dimerix’s ACTION3 Phase 3 trial to start after approval Lumos inks deals for test distinguishing viral from bacterial i... |
Stockhead | DXB | 6 months ago |
When $25 for board was daylight robbery
Women talk. But are we talking about the right things? Growing up in the 80s (I'm showing my age) my family didn't talk about finance, budgets or mortgages â I wish we had. I finished school with no responsibilities. I had no outgoings... |
Motley Fool | DXB | 6 months ago |
Why is the New Hope share price plunging today?
The New Hope Corp Ltd (ASX: NHC) share price is taking a tumble today. Shares in the S&P/ASX 200 Index (ASX: XJO) coal miner closed yesterday trading for $5.26. In early afternoon trade on Thursday, shares are swapping hands for $5.... |
Motley Fool | DXB | 6 months ago |
Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 7,818.3 points. Four ASX shares that have failed to follow the market higher today are l... |
Motley Fool | DXB | 6 months ago |
Why has this ASX mining stock exploded 128% in 2 days?
A little-known ASX mining stock is setting the bar high these past two days. Very high. At market close on Tuesday shares in Waratah Minerals Ltd (ASX: WTM) â previously known as Battery Minerals Limited â closed trading for 12.5 cents... |
Motley Fool | DXB | 6 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | DXB | 6 months ago |
If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!
Fancy grabbing a 917% one-year return from your ASX healthcare stock investment? Me too! The stock in question is clinical stage drug discovery and development company Dimerix Ltd (ASX: DXB) As you can likely guess by the phenomen... |
Motley Fool | DXB | 6 months ago |
2 ASX biotech shares that could be the next Telix Pharmaceuticals
Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)? You're not alone! The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to st... |
Motley Fool | DXB | 7 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | DXB | 7 months ago |
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks fall but Dimerix and Avita soar
ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis... |
Stockhead | DXB | 7 months ago |
Dimerix announces Middle East license agreement for DMX-200
Dimerix (ASX:DXB) has announced an exclusive license agreement with Taiba Middle East for the commercialisation of its candidate DMX-200. |
BiotechDispatch | DXB | 7 months ago |
Market Close: ASX edges up with mostly smiles on green dials
The ASX200 closed the day up 0.8%. All sectors bar one finished in the green. Real-estate lead the way, up 1.8%, tele-communications and staples followed, both gaining around 1.3%. The energy sector was the only sector to fall short,... |
themarketonline.com.au | DXB | 7 months ago |
Closing Bell: Rare earths hit launches 300pc small cap moon shot as ASX benchmark beards its bears
ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on Rare Earths find at the Tundulu project in Malawi Aussie shares rebounded pretty much across the boa... |
Stockhead | DXB | 7 months ago |
Market Update: ASX turns green with real estate flowering
The ASX200 is trading up around 0.7 per cent. Most sectors are in the green, real estate has gained the most so far, up nearly 1.6%. Staples follows, up 1.2%. The utilities and energy sectors are the only two to slip into the red.... |
themarketonline.com.au | DXB | 7 months ago |
Dimerix strikes $120m licensing deal for kidney drug in Middle East
Dimerix sells exclusive rights to register and commercialise DMX-200 for the treatment of kidney disease in key Middle East countries Dimerix to receive up to ~$120.5m from Taiba in upfront and milestone payments, plus royalties Second dea... |
Stockhead | DXB | 7 months ago |
ASX Health Stocks: EMV’s AI algo shows promise, and Telix submits new FDA application
EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai... |
Stockhead | DXB | 7 months ago |
CRITERION: Looking for a clinical approach to predicting trial outcomes? AI is there for you
Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747... |
Stockhead | DXB | 7 months ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | DXB | 7 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | DXB | 8 months ago |
Closing Bell: ASX meltdown as market awaits Fed; uranium diggers rebound
The ASX has plunged alongside Wall Street on jitters of higher US rates for longer All 11 sectors closed in the red Uranium stocks gathered some ground today The ASX200 has tumbled over 1% on Wednesday as hot US labour data sent jitters... |
Stockhead | DXB | 8 months ago |
Dimerix receives key paediatric investigation approval in UK
UK Regulatory Agency has given the greenlight for Dimerix’s DMX-200 Paediatric Investigation Plan The UK Paediatric Investigation Plan aims to ensure sufficient data is generated in Dimerix’s ACTION Phase 3 trial to allow for marketing app... |
Stockhead | DXB | 8 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | DXB | 8 months ago |
“Your Stock Request” – 28 March 2024
“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o... |
Fairmont Equities | DXB | 9 months ago |
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 3
Morgans says economic challenges have been catalyst for innovation and resilience in ASX health sector PharmAust submits supplementary data to US FDA from Phase 1 MEND study in support of its ODD request Singular health gets $1 million bac... |
Stockhead | DXB | 9 months ago |
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2
Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study Dimerix... |
Stockhead | DXB | 9 months ago |
Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200
Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease. |
BiotechDispatch | DXB | 9 months ago |
Closing Bell: ASX200 betrayed by big banks. Mollified by minnow metals
Local markets gives up early gains, ekes out 0.1pc advantage IT and Utilities offset by Energy sector losses Small Caps led by RMI and Narryer Metals We’re slightly higher at match out in Sydney. But big banks became bad banks after l... |
Stockhead | DXB | 9 months ago |
Dimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trial
Dimerix secures firm commitments for a $20m institutional placement ‘Highly strategic’ capital raise will see new institutional investors join the company’s register Proceeds will be used to advance the ACTION3 Phase 3 trial of DMX-200 in... |
Stockhead | DXB | 9 months ago |
Guess which ASX healthcare stock is rocketing 20% today
Dimerix Ltd (ASX: DXB) shares are taking off on Tuesday. In morning trade, the ASX healthcare stock is up 20% to a 52-week high of 36 cents. Why is this ASX healthcare stock jumping? The catalyst for this rise has been the successful compl... |
Motley Fool | DXB | 9 months ago |
DXB Announces Success on Interim Phase III Trial - China and US next for licensing deal?
Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB), just announced success on its interim Phase III clinical trial for FSGS - a rare kidney disease. |
nextinvestors.com | DXB | 9 months ago |
Closing Bell: Pretty shameless ASX taken to Task on Monday
Local markets get smashed, drop 1.8pc All 11 ASX sectors down Small Caps led by Task Group A record close on Friday has found a typically ASX200-flavoured follow-up on Monday after the last session in New York saw US semiconductor dar... |
Stockhead | DXB | 9 months ago |
‘A key milestone’: Dimerix ACTION3 Phase 3 trial interim results meet endpoint
Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis using proteinuria efficacy endpoint DMX-200 performing better than placebo in reducing proteinuria in patients with FSGS The trial’s IDMC says it has no safety conc... |
Stockhead | DXB | 9 months ago |
ASX Health Stocks: Dimerix ACTION3 Phase 3 interim trial results are out… and they’re good
Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis endpoint Mesoblast says US FDA supports accelerated approval pathway for rexlemestrocel-L Imexhs raises $1.5 million in cap raise to sophisticated and institutional i... |
Stockhead | DXB | 9 months ago |
Market Open: Backwards step to start a new week
There’s expected to be a more lacklustre session on the ASX200, after last week’s record-breaking performances. Futures tips the market will be down around about a half a per cent. US markets lost their steam on Friday and that saw te... |
themarketonline.com.au | DXB | 9 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | DXB | 10 months ago |
Closing Bell: Cettire rejects AFR claims, GDP’s gone back to the 90’s and ASX200 ends above the ice
Local markets end slightly higher IT Sector slumps 1.2pc Small Caps led by AT1 The ASX 200 traded sideways again today, closing the day +0.1% higher as gains in Financials and Real Estate were offset by losses in Tech and Mining stocks.... |
Stockhead | DXB | 10 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | DXB | 10 months ago |
Closing Bell: Staples go stupid as ASX200 proves it’s no Dow Jones, but it can be average
Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale The indignation of Coles has led Consumer... |
Stockhead | DXB | 10 months ago |
Dimerix announces successful collection of data for first patients in ACTION3 trial
Dimerix (ASX:DXB) has announced that data from the first 72 patients randomised in the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis has successfully been collected. |
BiotechDispatch | DXB | 10 months ago |
Q A: Dimerix CEO on upcoming milestone Phase III interim trial results
Dimerix first analysis results of Phase III trial into focal segmental glomerulosclerosis (FSGS) due in March Results are key milestone for Dimerix which has been working on its lead asset DMX-200 since around 2012 Dimerix finalised its fi... |
Stockhead | DXB | 10 months ago |
Closing Bell: Commodity prices, resurgent rate fears drag ASX to third straight loss
ASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led by diggers IXR, AW1 and the biopharma Alterity The ASX200 has ended lower on Wednesday, tracking losses in New York as traders brace – a... |
Stockhead | DXB | 10 months ago |
Dimerix gains on China drug application approval
Dimerix receives approval of investigational new drug application for ACTION3 trial in China No bridging studies required in the Chinese population prior to recruitment for trial Dimerix says the milestone approval may support partnering d... |
Stockhead | DXB | 1 year ago |
In Case You Missed It: AI-aged care deal, EV bank loans and some rare earths
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today. ICYMI Leade... |
Stockhead | DXB | 1 year ago |
Dimerix gains NMPA approval for IND, opening doors to global phase three tudy on FSGS Treatment
Dimerix (ASX:DXB) secures approval from the Chinese NMPA Centre for Drug Evaluation (CDE) for its IND application The approval greenlights the recruitment of 70 clinical sites across 11 countries, with further expansion plans post the an... |
themarketherald.com.au | DXB | 1 year ago |